Answers are grounded in this paper and cite their sources.
Background: CD4+ T cells constitute a major source of cytokines in allergic diseases such as allergic rhinitis. Interleukin (IL)‐16 selectively recruits CD4+ cells. Methods: We evaluated the effect of natural allergen exposure during a grass‐pollen season on IL‐16 expression and number of CD4+ cells in nasal mucosa. Patients with allergic rhinitis ( n =16) were treated with either a nasal glucocorticoid beclomethasone (BDP; 400 µg/day) or placebo, and gave nasal biopsies prior to and during the grass‐pollen season. The evaluated markers in allergic rhinitis patients were also compared to those in healthy control subjects ( n =5). Results: Prior to the pollen season, the expression of IL‐16, but not the number of CD4+ cells, was significantly higher in patients with allergic rhinitis than in healthy control subjects. The grass‐pollen season further increased IL‐16 expression and also increased the number of CD4+ cells in placebo‐treated, but not in BDP‐treated, allergic rhinitis patients. The pollen‐season‐induced change in IL‐16 expression and in CD4+ cells was significantly more pronounced in placebo‐ than in BDP‐treated patients. There was a significant correlation between the change in IL‐16 expression and the number of CD4+ cells. Conclusions: These data suggest that local upregulation of IL‐16 expression contributes to the inflammation observed in seasonal allergic rhinitis. Hypothetically, inhibition of IL‐16 expression can be one of several mechanisms by which nasal glucocorticoids achieve their anti‐inflammatory effect in allergic rhinitis.
No takes yet. Share an insight, caveat, or question.
Pullerits et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: